CellCentric: Funding, Investors & Team (Oct 2026)
Inobrodib is a capsule taken orally and is the first small molecule drug in clinical trials that targets the twin proteins p300 and CBP. These proteins are acetyl transferases and gene activators that are known to be involved in the development of certain cancers. CellCentric's innovative drug is currently being tested in Phase I/II clinical trials to determine its effectiveness in treating solid tumors and blood cancers, which are significant areas of unmet medical need in cancer treatment. This drug has the potential to provide a new therapy option for patients with limited alternatives.
CellCentric has raised $375M across 3 funding rounds on record, the most recent a Series D of $220M announced in May 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CellCentric Company Profile and Key Stats
Latest funding round on record: May 2026.
CellCentric Funding Rounds
CellCentric raised $35.0M in an undisclosed round announced in Jul 2024.
10 months later, a Series C of $120M was announced in May 2025.
1 years later, a Series D of $220M was announced in May 2026.
CellCentric Founders and Leadership Team
No contact details are on record for this team yet.
CellCentric Funding Compared to Other Biotechnology Startups
CellCentric's latest round of $220M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CellCentric in Biotechnology and Cambridge
Companies Similar to CellCentric
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
CellCentric Funding FAQs
What does CellCentric do?
Inobrodib is a capsule taken orally and is the first small molecule drug in clinical trials that targets the twin proteins p300 and CBP. These proteins are acetyl transferases and gene activators that are known to be involved in the development of certain cancers. CellCentric's innovative drug is currently being tested in Phase I/II clinical trials to determine its effectiveness in treating solid tumors and blood cancers, which are significant areas of unmet medical need in cancer treatment. This drug has the potential to provide a new therapy option for patients with limited alternatives.
How much funding has CellCentric raised?
CellCentric has raised $375M across 3 rounds on record. The most recent is a Series D of $220M announced in May 2026.
When did CellCentric last raise funding?
CellCentric's most recent funding round on record is a Series D of $220M, announced in May 2026.
Who founded CellCentric?
FundedIQ lists Will West (Founder) at CellCentric.
Where is CellCentric headquartered?
CellCentric is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does CellCentric have?
CellCentric is in the 11-50 employee band.
How does CellCentric's funding compare to other Biotechnology startups?
CellCentric's latest round of $220M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's CellCentric Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CellCentric is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.